Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 28

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 28
---
, and Favrille, Inc. (now MMR Global, Inc.), a publicly-traded clinical-stage drug development company, from 2001 to 2009. Earlier in her career, she spent eight years in public accounting with Deloitte & Touche LLP and PricewaterhouseCoopers LLP. Ms. Favorito is a certified public accountant (inactive). She received an MBA, emphasis in Finance, from Georgia State University, and a27
BBA, emphasis in Accounting, from Valdosta State University. Our Board believes that Ms. Favorito’s extensive experience in corporate management, finance and life science as chief financial officer of multiple public companies provides her with the qualifications and skills to serve as a director of our Company. Mr. Mangless has provided us with notice that he intends to nominate the Mangless Nominees for election as directors at the Annual Meeting. Although the Company is required to include the Mangless for election on its WHITEproxy card under universal proxy rules, for additional information regarding the Mangless Nominees and any other related information, please refer to Mr. Mangless’ proxy statement if and when it is provided to you by Mr. Mangless. You can access Mr. Mangless’ proxy statement, and any other relevant documents, without cost on the SEC’s website. The Board DOES NOTendorse the election of the Mangless Nominees. You may receive proxy solicitation materials from Mr. Mangless, including a proxy statement and blue proxy card.

| IF YOU DO RECEIVE SUCH PROXY MATERIALS FROM MR. MANGLESS, OUR BOARD STRONGLY URGES YOU TO DISCARD AND NOT TO SIGN OR RETURN MR. MANGLESS’S BLUE PROXY CARD OR TO VOTE FOR ANY OF THE MANGLESS NOMINEES. |

We believe that the director nominees proposed by our Board, with their breadth of relevant and diverse experience, are the most qualified candidates up for election at the Annual Meeting. Furthermore, our Board believes that the director nominees recommended and proposed by our Board would serve the interests of all of the Company’s stockholders better than the nominees proposed by one stockholder. If you have any questions or require any assistance with voting your shares, please contact Sodali & Co, our proxy solicitor assisting us in connection with the Annual Meeting: 430 Park Avenue, 14th Floor New York, New York 10022 Stockholders Call Toll-Free in North America: (800) 662-5200 Outside of North America Call Collect: